ternational
stant
cisive
formative
[email protected]/ [email protected] ASIA EDITION
www.biopectrumasia.com
"We Communicate
directly with
Life-Science
Leaders and
BioPharma
Executives
World-Wide"
www.biospectrumasia.com www.biospectrumindia.com
For More information , Please contact [email protected]
The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Keeping Pace with MUTATING VIRUSES
A surge in the pandemic has forced the pharma industry to deliver a wide-spectrum vaccine to fight mutation-prone SARS-CoV-2, pledging to prevent future outbreaks. WHO states that the
most extensive vaccination campaign in history is providing prophylactic results by delivering more than 12 billion doses of the COVID-19 vaccine, protecting 60 per cent of the global population as of June 2022. Now the next-generation COVID-19 vaccines are countering the
challenge of enhancing the immune response to tackle the emerging COVID-19 variants. It is therefore imperative to remain vigilant and upgrade vaccine candidates to emerging virus sublineages. In order to gain a competitive position in the market, vaccine manufacturers are
investing in advanced platform technologies. Let’s take a closer look at some of these leading vaccines approved in APAC as broad spectrum virucide inhibitors.
Discover the best professional documents and content resources in AnyFlip Document Base.
Search